Table 3.

Univariate and multivariate analysis of factors associated with survival following progression after CD19 CAR T-cell therapy

	Univariate analysis		Multivariate analysis
Parameter	HR (95% CI)	P	HR (95% CI)	P
Age (>40 vs ≤40 y)	1.64 (0.80-3.34)	.20	—	—
Sex (male vs female)	0.53 (0.21-1.34)	.20	—	—
Philadelphia chromosome–positive ALL (yes vs no)	0.63 (0.29-1.35)	.20	—	—
History of prior HSCT before CAR T cells (yes vs no)	0.63 (0.30-1.30)	.20	—	—
Prior blinatumomab or inotuzumab before CAR T cells (yes vs no)	1.78 (0.79-4.0)	.20	—	—
Bridging therapy before CAR T-cell infusion (no or nonintensive vs intensive)	0.36 (0.16-0.83)	.02	0.41 (0.14-1.16)	.09
Time from CAR T-cell infusion to relapse in months	0.94 (0.86-1.02)	.09	0.91 (0.83-1.00)	.04
BM blasts at the time of relapse	1.01 (1.00-1.03)	.08	1.01 (0.99-1.03)	.2
Extramedullary relapse (yes vs no)	0.85 (0.4-1.82)	.70	—	—
CD19 expression at relapse (positive vs negative)	0.63 (0.22-1.76)	.40	—	—
Salvage therapy after relapse (yes vs no)	0.48 (0.17-1.35)	.16	—	—
Blinatumomab or inotuzumab as salvage therapy after relapse (yes vs no)	1.41 (0.60-3.33)	.43	—	—

Factors with values of P ≤ .1 in univariate analysis were included in multivariate analysis.